G01N 2333/7156
For interferons [ifn]
Official title: for interferons [IFN]
G01N2333/7156 (For interferons [ifn]) appears on 9 US grants and 19 published applications in this corpus.
Search patents in G01N- Granted patents
- 9
- Published applications
- 19
- Assignees
- 17
- Inventors
- 49
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 2 |
| 2019 | 4 | 2 |
| 2020 | 2 | 1 |
| 2021 | 1 | 2 |
| 2022 | 0 | 3 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-IFNAR1 antibodies19 May 2026US 12,630,639 B2Immunecent Biotechnology, Inc.
- Spectrally filtered photodiode pair14 Oct 2025US 12,446,341 B2University of Massachusetts
- Anti-IFNAR1 antibodies for treating autoimmune diseases13 Jul 2021US 11,059,897 B2I-Mab Biopharma US Limited
- Methods of determining interferon having direct inhibitory effects on tumors and uses thereof29 Dec 2020US 10,877,024 B2Superlab Far East Limited
- Biomarkers for determining the clinical response to cell therapy18 Aug 2020US 10,746,729 B2TiGenix, S.A.U.
- Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies5 Feb 2026US 2026/0035460 A1Bristol-Myers Squibb Company
- In vitro method for the diagnosis and/or prognosis of multiple sclerosis8 May 2025US 2025/0147050 A1
- Novel screening platform to identify immune modulatory agents15 Feb 2024US 2024/0053325 A1President and Fellows of Harvard College
- Spectrally filtered photodiode pair1 Sep 2022US 2022/0278152 A1University of Massachusetts
- Novel anti-ifnar1 antibodies12 May 2022US 2022/0144957 A1Immunecent Biotechnology, Inc.
Most cited
By later US patents